These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 2374325)
21. Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer. Wang ZP; Chen YR; Zheng RL; Lu JZ; Wang JJ Acta Pharmacol Sin; 2002 Mar; 23(3):257-62. PubMed ID: 11918852 [TBL] [Abstract][Full Text] [Related]
22. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179 [TBL] [Abstract][Full Text] [Related]
23. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer. Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476 [TBL] [Abstract][Full Text] [Related]
24. [Dynamics of cytotoxicity of blood mononuclear cells in patients with bladder cancer during endolymphatic immunotherapy with lymphokine- activated killer cells and recombinant interleukin-2]. Malakhova NV; Figurin KM; Fedorova NS; Kiselevskiĭ MV; Bykovskaia SN Biull Eksp Biol Med; 1996 Feb; 121(2):188-91. PubMed ID: 9026128 [No Abstract] [Full Text] [Related]
26. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Mizutani Y; Bonavida B; Nio Y; Yoshida O Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609 [TBL] [Abstract][Full Text] [Related]
27. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272 [TBL] [Abstract][Full Text] [Related]
28. Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder. Moltó LM; Carballido JA; Manzano L; Olivier C; Lapuerta M; Alvarez-Mon M Int J Immunopharmacol; 1993 Apr; 15(3):335-41. PubMed ID: 8505146 [TBL] [Abstract][Full Text] [Related]
29. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro. Wang ZP; Zheng RL; Chen YR; Liu GD Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910 [TBL] [Abstract][Full Text] [Related]
30. [A study of immune surveillance for bladder tumor. III. The study of immunocompetence of tissue infiltrating lymphocytes in bladder tumors]. Tsujihashi H Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):977-84. PubMed ID: 3263530 [No Abstract] [Full Text] [Related]
31. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity. Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440 [TBL] [Abstract][Full Text] [Related]
32. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200 [TBL] [Abstract][Full Text] [Related]
33. In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro. Hancock GE; Molloy A; Ab BK; Kiessling R; Becx-Bleumink M; Cohn ZA; Kaplan G Cell Immunol; 1991 Feb; 132(2):277-84. PubMed ID: 1988157 [TBL] [Abstract][Full Text] [Related]
34. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid. Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887 [TBL] [Abstract][Full Text] [Related]
35. Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients. Sone S; Kunishige E; Fawzy F; Yanagawa H; Nii A; Maeda K; Atagi S; Heike Y; Nishioka Y; Mizuno K Jpn J Cancer Res; 1991 Jun; 82(6):716-23. PubMed ID: 1649813 [TBL] [Abstract][Full Text] [Related]
37. [Characterization of lymphokine-activated killer cells obtained from the natural killers--T cells of patients with hepatic tumor lesion]. Vershinina MIu; Khalturina EO; Patiutko IuI; Zabezhinskiĭ DA; Titov KS; Lebedinskaia OV; Vorob'ev AA; Kiselevskiĭ MV; Kuzovlev EN Vestn Ross Akad Med Nauk; 2004; (12):32-6. PubMed ID: 15678686 [TBL] [Abstract][Full Text] [Related]
38. Lysis of primary hepatic tumours by lymphokine activated killer cells. Hsieh KH; Shu SY; Lee CS; Chu CT; Yang CS; Chang KJ Gut; 1987 Feb; 28(2):117-24. PubMed ID: 3030899 [TBL] [Abstract][Full Text] [Related]
39. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer. Wang Z; Cheng Y; Zheng R; Qin D; Liu G Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335 [TBL] [Abstract][Full Text] [Related]
40. Lymphokine-activated killer activity in women with endometriosis. Oosterlynck DJ; Lacquet FA; Waer M; Koninckx PR Gynecol Obstet Invest; 1994; 37(3):185-90. PubMed ID: 8005550 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]